Evgen Pharma Share Price (EVG)

Should be interesting to see who the new CEO will be. Gla ;-)

MANAGEMENT

It is a reflection of the very significant potential of Evgen Pharma’s technology that the company has been able to attract a high calibre commercial, scientific and advisory team.

SALLY ROSS, CLINICAL DEVELOPMENT OFFICER

Sally has over 18 years of experience working across pre-clinical and clinical settings in academia, pharma and CROs.  Sally held many different roles at AstraZeneca, starting off as a translational Scientist working on Iressa and then moved into more clinical roles as a Global Project/Programme Manager in the Oncology and Infection Therapeutic Areas, and subsequently as a Principal Medical Scientist in both early and late clinical development. Upon leaving AstraZeneca Sally worked for a large mid-sized contract research organisation as Director of Project Management.

CONSULTANTSDR THOMAS MORRIS – MEDICAL ADVISOR

Tom is a physician who has worked in pharmaceutical medicine and drug development for over 20 years with much of this time specialising in oncology. After several years working in clinical medicine, he joined firstly Medeval Ltd (University of Manchester) and then AstraZeneca, where he has held a number of global R&D roles. Most recently these included Senior Medical Director and Executive Director Clinical Programs. He has overseen several global drug development programs, interacting with leading external medical and scientific experts, academic groups and regulatory agencies.

 0

Another strong Astazeneca connection. Gla ;-)

DR ALAN BARGE, NON-EXECUTIVE DIRECTOR

Alan is the former chief medical officer of Singapore-based ASLAN Pharmaceuticals PTE. Up until 2011, he was vice-president and head of oncology & infection at AstraZeneca, a role in which he was responsible for the overall strategy in oncology and infection from drug discovery to pr1oof-of-concept. He was also chairman of AstraZeneca’s Therapy Area Portfolio Team and accountable for the design and delivery of all projects, including budgetary oversight. Prior to his career at AstraZeneca, Alan was European and global medical director for Amgen Inc.

https://evgen.com/about/management/

Watch this space Daddio, EVG is still under the Radar, as we await potential Transformational funding news for SFX-01 to enter Covid-19 patient trials, speculation of which was considered rubbish by your good self, until the Rns confirmed they were in discussions ....news could drop at anytime....Gla Holders!!! :-)

Sadly it now seems to be a case of no moneymunch rather hotairbrigademunch, son